Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15658842 | 0.80 | CA1 (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL50047 | 0.80 | CA1 (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL5691177 | 0.80 | CA1 (0.65) | CA1CA2CA7CA9CA12 | |
| Hydrochloric Acid SCHEMBL29193799 | 0.79 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| Bromide SCHEMBL28452838 | 0.79 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| 1,4-Dimethoxybenzene SCHEMBL8489 | 0.78 | CA1 (1.00) | CA1CA2CA7CA9CA12 | |
| 1,4-Dimethoxybenzene SCHEMBL21802643 | 0.78 | CA1 (1.00) | CA1CA2CA7CA9CA12 | |
| SCHEMBL31328597 | 0.78 | CA1 (0.61) | CA1CA2CA7CA9CA12 | |
| SCHEMBL5713323 | 0.78 | CA1 (0.61) | CA1CA2CA7CA9CA12 | |
| SCHEMBL31378153 | 0.78 | CA1 (0.61) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238667-B2 | Rhodium catalyst and method for producing amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20150051416-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | SPERA PHARMA, INC. (JP) | 2015-02-19 | — | — | US | disclosed |
| EP-2832738-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-04 | — | — | EP | disclosed |
| EP-1626052-B1 | PROCESS FOR PRODUCTION OF PHOSPHINE-BORANE COMPLEXES | TAKEDA PHARMACEUTICAL (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-8053604-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20100125153-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | SPERA PHARMA, INC. (JP) | 2010-05-20 | — | — | US | disclosed |
| US-7678942-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-16 | — | — | US | disclosed |
| EP-1452537-B1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-05 | — | — | EP | disclosed |
| US-7541498-B2 | Process for production of phosphine-borane complexes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541498-B2 | Process for production of phosphine-borane complexes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | SPERA PHARMA, INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20060199968-A1 | Process for production of phosphine-borane complexes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1626052-A1 | PROCESS FOR PRODUCTION OF PHOSPHINE-BORANE COMPLEXES | Takeda Pharmaceutical Company Limited (JP) | 2006-02-15 | — | — | EP | disclosed |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | SPERA PHARMA, INC. (JP) | 2005-02-03 | — | — | US | disclosed |
| EP-1452537-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | Takeda Chemical Industries, Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125153-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | H1-10, ITPA, RER1 | CA1 1262/4885CA2 806/4885CA7 1495/4885 |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | BACE1, H1-10, PRMT1 | CA1 109/4885CA2 503/4885CA7 984/4885 |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | H1-10, ITPA, RER1 | CA1 1306/4885CA2 841/4885CA7 1519/4885 |
| US-20150051416-A1 | RHODIUM CATALYST AND METHOD FOR PRODUCING AMINE COMPOUND | PRMT7, PRMT5, HNMT | CA1 1790/4885CA2 2153/4885CA7 584/4885 |
| US-20060199968-A1 | Process for production of phosphine-borane complexes | BRS3, BRPF1, BRSK1 | CA1 1369/4885CA2 725/4885CA7 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.